Aclaris Therapeutics Inc. share price logo

Aclaris Therapeutics Inc.

NASDAQ: ACRS

Small Cap

$4.50

+0.08

(+1.81%)

as on

Aclaris Therapeutics Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $4.37
    $4.58
    downward going graph

    2.89%

    Downside

    1.78%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.34
    $5.15
    downward going graph

    70.16%

    Downside

    14.44%

    Upside

    downward going graph

Aclaris Therapeutics Inc. share price movements today

Previous Close
$4.42
Open
$4.54
Volume
1.4M
Day's Low - High
$4.37 - $4.58
52 Week Low - High
$1.34 - $5.15

Aclaris Therapeutics Inc. Historical Returns

1 Month Return
+ 1.12 %
3 Month Return
+ 20.32 %
1 Year Return
+ 216.9 %
3 Year Return
-55.97 %
5 Year Return
-75.4 %

Aclaris Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Aclaris Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$615.9M

EPS (TTM)

-0.655

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-0.13

EBITDA

-78.5M

Revenue (TTM)

8.4M

Profit Margin

0.00%

Return On Equity TTM

-48.42%

Aclaris Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aclaris Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Aclaris Therapeutics Inc. image
Aclaris Therapeutics Inc.
HOLD$615.9M-75.4%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Aclaris Therapeutics Inc. Stock including INR - Dollar returns

The Aclaris Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Aclaris Therapeutics Inc. investment value today

Current value as on today

₹3,45,195

Returns

₹2,45,195

(+245.19%)

Returns from Aclaris Therapeutics Inc. Stock

₹2,16,901 (+216.9%)

Dollar Impact

₹28,293 (+28.29%)

Analyst Recommendation on Aclaris Therapeutics Inc. Stock

Based on 15 analysts

HOLD

40.00%

Buy

60.00%

Hold

0.00%

Sell

Based on 15 analysts, 60% of analysts recommend a 'HOLD' rating for Aclaris Therapeutics Inc.. Average target price of $10

Aclaris Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Aclaris Therapeutics Inc..

What analysts predicted

55%UPSIDE

Target Price

$10

Current Price

$4.5

Analyzed by

15 Analysts

Target

$10.00

Aclaris Therapeutics Inc. target price $10, a slight upside of 55% compared to current price of $4.5. According to 15 analysts rating.

Indian Investors' Interest in Aclaris Therapeutics Inc. Stock

Search interest for Aclaris Therapeutics Inc. Stock has increased by 7% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:7% versus previous 30 day period

Aclaris Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
17
2
2
4
9
1
1
3
1
1
Gross Profit
11
0
0
1
0
0
0
2
2
1
Operating Income
-4
-18
-12
-10
-99
-18
-18
-17
-22
-22
EBITDA
-23
-15
-12
-9
-13
-17
-16
-14
-19
-19
Interest Expense
1
-
-
-
4
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-1
-16
-10
-7
-96
-15
-15
-14
-19
-19
Income Tax Expense
0
0
-
-7
-
-
-
-
-
-
Net Income
-1
-16
-10
-7
-96
-15
-15
-14
-19
-19
Net Profit Margin
-8.49%
-706.46%
-397.18%
-174.55%
-1048.22%
-1036.77%
-868.26%
-442.98%
-1528.57%
-993.19%

Aclaris Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
1
10
4
6
6
29
31
18
7
Gross Profit
0
0
3
0
1
2
17
13
15
5
Operating Income
-48
-72
-135
-111
-50
-89
-89
-97
-141
-76
EBITDA
-48
-72
-133
-90
-49
-64
-84
-115
-51
-64
Interest Expense
-
-
-
-
1
23
4
-
-
-
Depreciation
-
0
1
6
1
0
0
0
0
0
Income Before Tax
-48
-70
-132
-113
-51
-90
-86
-88
-132
-64
Income Tax Expense
0
-1
2
29
0
23
1
0
-
-
Net Income
-48
-68
-132
-161
-51
-90
-86
-88
-132
-64
Net Profit Margin
0.00%
-4071.48%
-1315.41%
-3817.22%
-789.17%
-1343.96%
-292.11%
-283.15%
-705.48%
-829.58%

Aclaris Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-16
-10
-7
-96
-15
-15
-14
-19
-19
Operating Cash Flow
-20
-12
22
-8
-13
-9
-10
-13
-18
Investing Cash Flow
16
0
2
-88
19
5
13
10
-30
Financing Cash Flow
0
0
0
74
0
0
-3
-2
57
Change in Cash
-4
-13
24
-23
5
-4
0
-5
8

Aclaris Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-68
-132
-113
-51
-90
-86
-88
-132
-64
Operating Cash Flow
-54
-100
-96
-38
-52
-67
-78
-20
-47
Investing Cash Flow
-55
9
105
6
-167
12
46
-69
48
Financing Cash Flow
100
128
-30
18
225
72
26
74
-5
Change in Cash
-9
36
-21
-13
5
17
-5
-15
-4

Global Institutional Holdings in Aclaris Therapeutics Inc.

Funds
Holdings
BML Capital Management LLC
10.2%
RA Capital Management, LLC
4.87%
Acadian Asset Management LLC
1.1%
Vanguard Group Inc
4.66%
Marshall Wace Asset Management Ltd
1.42%
See all

Insights on Aclaris Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.29M → 1.99M (in $), with an average increase of 35.1% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, ACRS stock has moved up by 210.3%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ACRS has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Aclaris Therapeutics, Inc. Common Stock has experienced a drawdown of -57.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 36.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -14.61M → -19.82M (in $), with an average decrease of 17.8% per quarter

About Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
OrganisationAclaris Therapeutics Inc.
Headquarters701 Lee Road, Wayne, PA, United States, 19087
IndustryBiotechnology
CEODr. Neal S. Walker D.O., M.D.
E-voting on sharesClick here to vote

Key Management of Aclaris Therapeutics Inc.

Name

Title

Dr. Neal S. Walker D.O., M.D.

Co-Founder, CEO & Chairman

Dr. Hugh M. Davis Ph.D.

President, COO & Director

Mr. Kevin Balthaser

Chief Financial Officer

Dr. Roland Kolbeck Ph.D.

Chief Scientific Officer

Dr. Jesse W. Hall M.D.

Chief Medical Officer

Mr. James Loerop

Chief Business Officer

Mr. William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

Mr. Matthew Rothman J.D.

General Counsel & Corporate Secretary

Mr. Steve Tucker

Executive Vice President of Project Leadership

Ms. Nina Samra M.S.

Senior Vice President of Clinical Operations

FAQs

What is Aclaris Therapeutics Inc. share price today?

Aclaris Therapeutics Inc. share price today is $4.5 as on at the close of the market. Aclaris Therapeutics Inc. share today touched a day high of $4.58 and a low of $4.37.

What is the 52 week high and 52 week low for Aclaris Therapeutics Inc. share?

Aclaris Therapeutics Inc. share touched a 52 week high of $5.15 on and a 52 week low of $1.34 on . Aclaris Therapeutics Inc. stock price today i.e. is closed at $4.5,which is 12.62% down from its 52 week high and 235.17% up from its 52 week low.

What is Aclaris Therapeutics Inc.'s market capitalisation today?

Aclaris Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Aclaris Therapeutics Inc. Stock (ACRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aclaris Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aclaris Therapeutics Inc. Shares that will get you 0.3333 shares as per Aclaris Therapeutics Inc. share price of $4.5 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Aclaris Therapeutics Inc. Stock (ACRS) from India?

Indian investors can start investing in Aclaris Therapeutics Inc. (ACRS) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Aclaris Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Aclaris Therapeutics Inc. share’s latest price of $4.5 as on June 19, 2026 at 8:46 am IST, you will get 2.2222 shares of Aclaris Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Aclaris Therapeutics Inc. has given to Indian investors in the last 5 years?

Aclaris Therapeutics Inc. stock has given -75.4% share price returns and 27.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?